Anti-NUT (clone QR043)

NUT Carcinoma (NUT Carcinoma, NC) – A Rare and Aggressive Subtype of Squamous Cell Carcinoma
NUT Carcinoma (formerly NUT Midline Carcinoma, NMC) is a rare and exceptionally aggressive subtype of squamous cell carcinoma characterized by chromosomal rearrangement of the NUT gene (NUTM1, nuclear protein in testis).
Location and Epidemiology
✔ Primarily arises along the body's midline, affecting:
  
Thoracic region (~50%) – chest, mediastinum, lungs
  
Head and neck (~40%)
✔ Less commonly found in extramidline locations such as:
  
Salivary gland
  
Pancreas
  
Bladder
  
Kidney
  
Adrenal glands
  
Soft tissues and bones
NUT carcinoma is almost universally fatal, with a median overall survival of 6.5 months. It can occur at any age but is most frequently diagnosed in teenagers and young adults, with a median age of 24 years.
Pathogenesis – The Role of BRD4-NUT Fusion Oncoproteins
✔ In ~75% of cases, NUT fuses with BRD4, creating the potent oncoprotein BRD4-NUT.
✔ Alternative translocations may involve NUT fusion with other partners, including:
  
BRD3
  
NSD3
  
ZNF532
  
ZNF592
✔ These fusion proteins interact with BRD4, leading to dysregulated transcription and oncogenic transformation.
Diagnosis of NUT Carcinoma
✔ Immunohistochemistry (IHC) for NUT nuclear staining is the primary diagnostic method.
✔ Molecular tests such as FISH or RT-PCR are used in ambiguous cases to confirm NUT gene translocation.
Summary
✔ NUT carcinoma is an extremely aggressive cancer, with a median survival of only 6.5 months.
✔ It predominantly affects the midline structures (thoracic region, head, and neck) but can also arise in other locations.
✔ Its pathogenesis is driven by chromosomal translocations, resulting in the expression of oncogenic BRD4-NUT fusion proteins and related variants.
✔ Diagnosis relies on immunohistochemical detection of NUT and molecular genetic analyses.